Subscribe
Urology Practice Management - June 2015, Vol 4, No 3 - Urologic Cancers
Rosemary Frei, MSc

A new analysis suggests that adherence to guidelines for follow-up care in patients who have undergone a radical cystectomy may standardize care but may also increase expenditures compared with the cost of most current approaches, which are more conservative and deviate from existing guidelines. The study, published recently in Urologic Oncology, examined the sources of variation in care and the cost associated with standardizing care to recommended guidelines.1

Until now, standard approaches to follow up with patients in the 2 years after they undergo a radical cystectomy have been poorly defined, noted lead investigator Seth A. Strope, MD, MPH, Assistant Professor of Surgery, Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO, and colleagues. To evaluate variations in follow-up care, the investigators performed a population-based study using Surveillance, Epidemiology, and End Results (SEER) Medicare data. The cost associated with standardizing care based on current guidelines was also evaluated.

All but 25% of patients with bladder cancer aged between 66 and 90 years undergoing radical cystectomy had less expensive follow-ups than would be incurred using even a low-intensity set of recommendations in the National Comprehensive Cancer Network (NCCN) guidelines. Patients also had less expensive follow-ups than if their physicians had used the European Association of Urology (EAU) guidelines for their postradical cystectomy care. The investigators also found that imaging accounted for most of the cost in both guideline-recommended care and actual clinical practice.

Deviating from Recommended Guidelines

“Despite the 2 prevailing recommendations for relatively intensive surveillance following extirpative surgery for bladder cancer, our analysis of current practice patterns suggests that providers are conducting a more conservative approach that is, for the most part, less costly than published guidelines,” the investigators wrote. “Greater compliance with current guidelines would actually increase expenditures for payers and patients. Additionally, strict adherence to follow-up protocols may restrict patients’ choice, potentially negatively affecting patient’s quality of life.”

However, Dr Strope noted that there is much more work that needs to be done to determine what is truly the best care for patients.

“Current research suggests the survival benefit of follow-up testing after definitive bladder cancer surgery is small,” Dr Strope told Urology Practice Management. “In the absence of stronger evidence to support intensive follow-up after surgery, more conservative approaches appear indicated.”

Evaluating Variability and Cost


The team modeled the variability in expenditures for follow-up care as well as how much of the variability could be explained by various factors, such as those specific to the patients or their surgeons. They found that patient-specific factors—primarily nodal status, use of chemotherapy, hospital readmissions, and final disease stage—represented the majority of variation in expenditures. Surgeon-specific factors also accounted for a significant amount of the variability.

In the second part of the study, Dr Strope and colleagues calculated what the patients’ cost of follow-up care would be if the physicians were using NCCN guidelines for high-intensity or low-intensity (ie, conservative) care, or the EAU guidelines, and compared it with the 25th, 50th, and 75th percentiles of cost of care among SEER-database patients.

The guideline-recommended care was more expensive than actual care in every comparison except one: the NCCN conservative follow-up versus the 75th percentile of actual-care cost ($1384 vs $1737). The highest estimated cost was for NCCN-recommended high-intensity follow-up, at $4833. The second-highest was for EAU-recommended follow-up for patients with bladder cancer staged at >2, at $4071. Imaging accounted for the majority of the cost in every category, both actual and estimated.

The team concluded that adherence to published guidelines may boost costs of follow-up care; however, adherence to conservative guidelines would facilitate standardization of care without producing large increases in cost.

Reference

  1. Vemana G, Vetter J, Chen L, et al. Sources of variation in follow-up expenditure after radical cystectomy. Urol Oncol. 2015 Apr 20 [Epub ahead of print].
Related Items
Tadalafil Significantly Reduces Symptoms of Erectile Dysfunction and LUTS/BPH
Rosemary Frei, MSc
Urology Practice Management - April 2016, Vol 5, No 2 published on May 4, 2016 in Erectile Dysfunction
ACR Responds to Continued Expansion of Physician Compare
Rosemary Frei, MSc
Rheumatology Practice Management February 2016 Vol 4 No 1 published on March 10, 2016 in Medicare
Boosting Blueberry Intake May Keep Erectile Dysfunction Risk at Bay
Rosemary Frei, MSc
Urology Practice Management - February 2016, Vol 5, No 1 published on February 19, 2016 in Erectile Dysfunction
CMS Reimbursement Policies Resulted in Overuse of Office-Based Cystoscopic Procedures
Rosemary Frei, MSc
Urology Practice Management - February 2016, Vol 5, No 1 published on February 19, 2016 in Reimbursement
CMS Unveils Equity Plan to Improve Quality, Increase Access to Care
Rosemary Frei, MSc
Urology Practice Management - December 2015, Vol 4, No 6 published on December 28, 2015 in Health Policy
Bladder Cancer Tumor Staging Postchemotherapy Accurately Predicts Survival
Rosemary Frei, MSc
Urology Practice Management - December 2015, Vol 4, No 6 published on December 28, 2015 in Bladder Cancer
New Mobile App Lets Men with LUTS Go with the Flow
Rosemary Frei, MSc
Urology Practice Management - December 2015, Vol 4, No 6 published on December 28, 2015 in Urinary Tract Symptoms
Medicare Will Begin Reimbursing for Advance Care Planning Discussions in 2016
Rosemary Frei, MSc
Oncology Practice Management - December 2015, Vol 5, No 9 published on December 22, 2015 in Reimbursement
CMS Unveils Equity Plan to Improve Access to Care, Patient Outcomes
Rosemary Frei, MSc
Oncology Practice Management - November 2015, Vol 5, No 8 published on November 11, 2015 in Health Policy
Job Searches and Contract Negotiations: Advice from Experts
Rosemary Frei, MSc
Rheumatology Practice Management October 2015 Vol 3 No 5 published on November 2, 2015 in Employment Strategies
Last modified: June 15, 2015
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search